We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Byotrol Plc | LSE:BYOT | London | Ordinary Share | GB00B0999995 | ORDS 0.01P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.125 | 0.05 | 0.20 | 0.125 | 0.125 | 0.13 | 447,501 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Chemicals & Chem Preps, Nec | 4.59M | -1.69M | -0.0037 | -0.32 | 544.67k |
Date | Subject | Author | Discuss |
---|---|---|---|
16/6/2015 10:31 | At least cash usage fell to circa £50k per month over the past six months. If this could be halved to say £25k pm then cash would not run out until the second half. I also have a concern over inventories and debtors.If the formulations are needing to be changed,this might generate unusable stock both in respect of held and sold product . | mudbath | |
15/6/2015 14:52 | maybe he thinks his shareholders are a weird bunch too. | emeraldzebra | |
15/6/2015 12:11 | The employees and directors should be out on their ears if the shareholders don't do well. The chairman's statement is peculiar. | brownson | |
15/6/2015 09:20 | (On an undulating playing field.) Did I miss it,or was there indeed no reference to profitability being achieved in 2015,2016 ? If the one off payment received in 2014 had been quantified and shown as an exceptional item,the BOD would not now be struggling to explain the disappointing comparatives. Reformulations will always be required,just as regulation never rests. As in the previous year,today's prelims provide no visibility. Paragraphs such as, In July 2014 the Board awarded options over a total of 16.66 million shares to current employees and Directors. This equates to 7.5% of our current issued share capital of 225 million shares. "The options are all exercisable at a strike price of 3.5p but vest in tranches depending on the share price reaching 5p, 7.5p or 10p. If we assume that all employees stay with us and that our share price rises to 10p and that they all choose to exercise their options awarded in July 2014 in full then it might be constructive to see what effect that has on our shareholders. The Company will receive cash of GBP581,000 and will issue 16.66 million shares. Now, assuming that the Company uses this money to buy back those shares in the market, then the number of new shares issued falls to 10.85 million, which means that our existing shareholders will have been diluted by 4.8%. Just as important as the scenario where we all do well is to look at mediocre performance. No employee will benefit unless our share price reaches at least 5p, an increase of 66% over the price at which we raised funds in 2014. Even at that level the rewards to the employees are modest and the dilution to our shareholders is less than 1%. There is no free ride and in fact employees only benefit in a meaningful way if the shareholders do very well." really are not worth incuding,imo. Roll on 2017 . | mudbath | |
15/6/2015 07:59 | It sounds like the goalposts keep moving. | maxk | |
15/6/2015 07:47 | Results out, as i expected, some quirky words from David.. Outlook Whilst the year in review was by no means easy, we are pleased with what we have achieved. The financial performance is not yet where we need it to be, but it is steadily improving and the quality of our products is improving in leaps and bounds. At the centre of these technical improvements is a fundamental rethink of our core technology, prompted by market demands and by regulatory change. Byotrol was for many years a single technology company, based on a combination of biocides and a silicone polymer. Having completed many strands of R&D work, we are now a multi-technology company with several chemistries, designed for - and tailored to - many different pockets of anti-microbial demand; we will make much more of this in our marketing in the coming year. Having completed the majority of technical work, we are now turning more aggressively to sales, using our own resources and those from alliances, agents and exclusive partnerships. We would certainly like to expand our own in-house sales force substantially, but we will only increase overheads as sales and margins allow. | battlebus2 | |
09/6/2015 16:01 | Yup, I saw that on the BBC this morning. The article claims to be using 'detergent' based wipes which could explain the poor results, really need anti-bacterial for best protection. Maybe a talking point with current NHS discussions? | shroder | |
09/6/2015 10:49 | Interesting story over wipes on the Tristel board. | battlebus2 | |
08/6/2015 14:02 | Depends on the definition of life. Heart may be beating but brain can be dead | brownson | |
07/6/2015 17:55 | Hoping our buyer surface's again this week. It would be nice to come off the lows as we head into earnings.. | shroder | |
04/6/2015 15:26 | That looks promising, a 'B' trade, normally relates to a worked buy or sell. We really need the larger stake holders to mop up the seller. | shroder | |
02/6/2015 16:13 | lol, we have all been there although I will be looking to add hopefully soon. Occasionally (very occasionally) one has a bit of luck, mine came in the form of Barclay's making a complete hash of an ISA transfer. As a result I ended up selling 1m shares on that last bounce pre-April 5th. I still give them a hard time about it..lol | shroder | |
02/6/2015 16:04 | I can only assume that I was temporarily possessed. I certainly won't be adding and will be looking to offload if I can do so without too much pain. | brownson | |
02/6/2015 15:59 | I would agree with you brownson if it were not for new management. This is a completely different company under David's stewardship, this includes reformulated products pending new Euro regs. What prompted your decision to buy more? | shroder | |
02/6/2015 15:27 | I'm afraid any hope of surprise news is just pie in the sky. I've been listening to the same old rubbish from the company about US licensing and EU licensing for as long as I can remember. Same applies to profitability. It just ain't gonna happen. Expect a buyout by a larger company at about the 2p mark as it continues to fall. | brownson | |
02/6/2015 15:15 | Drives you nuts.. | shroder | |
02/6/2015 13:50 | Agreed battlebus, although it still looks like we have one or two stale bulls. Any unexpected news (NHS/US approval) could turn this on it's head. | shroder | |
31/5/2015 14:31 | I would hope not shroder, surely in time we will be trading a lot higher. | battlebus2 | |
31/5/2015 14:16 | Didn't we see a similar report towards the end of last year on campylobacter? It would be nice to see the share price above 4p (and hold, perhaps the current seller is someone who took part in the placing taking a small turn. | shroder | |
27/5/2015 17:46 | Sorry, can't reach the keyboard from the floor, lol | shroder | |
27/5/2015 12:16 | Indeed, i've come over all blue.... | battlebus2 | |
26/5/2015 14:45 | I'm glad you have some left. Mine went a long time ago | brownson |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions